NPT 088

Drug Profile

NPT 088

Alternative Names: NPT-088

Latest Information Update: 20 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator NeuroPhage Pharmaceuticals Inc
  • Developer Proclara Biosciences
  • Class Antiparkinsonians; Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Nootropics; Recombinant fusion proteins
  • Mechanism of Action Alpha-synuclein modulators; Amyloid beta-protein modulators; Protein aggregation inhibitors; Tau protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease
  • Preclinical Parkinson's disease

Most Recent Events

  • 17 Jul 2017 Data Monitoring Committee recommends continuation of phase Ib trial
  • 16 Nov 2016 Proclara Biosciences has patent protection for General Amyloid Interaction Motif (GAIM) in USA
  • 19 Sep 2016 Preclinical trials still ongoing in Parkinson's disease in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top